| Gene symbol | CD40LG | Synonyms | CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD40 ligand | ||||
| Gene symbol | CD70 | Synonyms | CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.3 | dbXrefs | |
| Description | CD70 molecule | ||||
| Gene symbol | TLR4 | Synonyms | ARMD10, CD284, TLR-4, TOLL | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | toll like receptor 4 | ||||
| GTO ID | GTC2038 |
| Trial ID | NCT03788083 |
| Disease | Breast Cancer |
| Altered gene | CD40LG|TLR4|CD70 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | TriMix |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Study on the Safety and Immune-modulatory Effect of Intratumoral (i.T.) Administration of mRNA (Messenger RNA) Encoding Dendritic Cell Activating Proteins in Patients With Early, Resectable Breast Cancer |
| Year | 2018 |
| Country | Belgium |
| Company sponsor | Universitair Ziekenhuis Brussel |
| Other ID(s) | TriMix-Breast |
| Cohort1: Placebo | |||||||||
|
|||||||||
| Cohort2: TriMix_dose Level | |||||||||
|
|||||||||
| Cohort3: TriMix_dose Leve2 | |||||||||
|
|||||||||
| Cohort4: TriMix_dose Leve3 | |||||||||
|
|||||||||